Search Results - "Vinnyk, Yurii"

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis by Baranova, Anna, Krasnoselskyi, Mykola, Starikov, Volodymyr, Kartashov, Sergii, Zhulkevych, Igor, Vlasenko, Vadym, Oleshko, Kateryna, Bilodid, Olga, Sadchikova, Marina, Vinnyk, Yurii

“…Breast cancer is the most common cancer in women and the most common cause of death in working-age women. According to the results of immunohistochemical…”
Get full text

Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC by Filon, Olga, Orlov, Sergey, Burdaeva, Olga, Kopp, Mikhail V., Kotiv, Bogdan, Alekseev, Sergiy, Pecheniy, Aleksandr, Stroyakovskiy, Daniil, Gladkov, Oleg, Khorinko, Andrey, Matrosova, Marina, Galiulin, Rinat, Skopin, Pavel, Mukhametsina, Guzel, Odarchenko, Sergey, Kulik, Sergey, Kulyaba, Jaroslav, Adamchuk, Grigory, Vinnyk, Yurii, Tjulandin, Sergei

“…Abstract only…”
Get full text

Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment by Im, Young-Hyuck, Odarchenko, Petro, Grecea, Daniela, Komov, Dmitry, Anatoliy, Chernobay Valentynovych, Gupta, Sudeep, Shparyk, Yaroslav V., Caguioa, Priscilla B., Makhson, Anatoly, Krasnozhon, Dmitriy, Li, Rubi Khaw, Noryk, Dzmitry, Vinnyk, Yurii Oleksiiovych, Nemsadze, Gia, Kim, Ho Ung, Lee, Sang-Joon

“…Abstract only 629 Background: CT-P6(C) is an anti-HER2 MoAb, a biosimilar to trastuzumab (T). This trial is a global phase III study to compare C with T, both…”
Get full text

Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator’s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanib—LUX-Lung 5 (LL5) by Schuler, Martin H., Yang, Chih-Hsin, Park, Keunchil, Bennouna, Jaafar, Chen, Yuh-Min, Chouaid, Christos, De Marinis, Filippo, Feng, Ji Feng, Grossi, Francesco, Kim, Dong-Wan, Liu, Xiaoqing, Lu, Shun, Strausz, Janos, Vinnyk, Yurii, Wiewrodt, Rainer, Zhou, Caicun, Chand, Vikram K., Wang, Bushi, Kim, Joo-Hang, Planchard, David

“…Abstract only…”
Get full text